Ligand Pharmaceuticals | LGND - Cash And Equivalent


Ligand Pharmaceuticals reported $664.52M in Cash and Equivalent for its fiscal quarter ending in September of 2025.





Cash And Equivalent Change Date
Amgen USD 9.13B 316M Dec/2025
Arrowhead Research USD 88.71M 41.09M Sep/2025
Baxter International USD 1.73B 40M Sep/2025
Bristol-Myers Squibb USD 15.73B 3.13B Sep/2025
Eli Lilly USD 9.79B 6.42B Sep/2025
Gilead Sciences USD 5.14B 2.78B Jun/2025
GlaxoSmithKline GBP 3.3B 303M Sep/2025
Glaxosmithkline GBP 3.3B 303M Sep/2025
Insmed USD 334.76M 949.56M Sep/2025
Ionis Pharmaceuticals USD 2.24B 1.94B Sep/2025
Ligand Pharmaceuticals USD 664.52M 596.85M Sep/2025
MacroGenics USD 80.13M 50.56M Sep/2025
Merck USD 18.17B 10.16B Sep/2025
Pacira USD 147.59M 152.89M Sep/2025
Pfizer USD 1.34B 295M Sep/2025
Veracyte USD 315.57M 96.07M Sep/2025